FT-011

Research use only, not for human use.

A novel anti-fibrotic agent that prevents TGF-beta-stimulated production of collagen in cultured renal mesangial cells (55-70% inhibition at 30 uM).

A novel anti-fibrotic agent that prevents TGF-beta-stimulated production of collagen in cultured renal mesangial cells (55-70% inhibition at 30 uM); inhibits both TGF-β1 and PDGF-BB induced collagen production as well as PDGF-BB-mediated mesangial proliferation, attenuates the decline in GFR, proteinuria and glomerulosclerosis in a robust model of non-diabetic kidney disease; attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.(In Vivo):FT011 (100 mg/kg b.i.d., p.o., for 4 weeks) improves the cardiac function and and myocardial remodeling in myocardial infarction rats.

——

FT011 (100 mg/kg b.i.d., p.o., for 4 weeks) improves the cardiac function and and myocardial remodeling in myocardial infarction rats. Animal Model:Seventy male Sprague Dawley (SD) rats (weighing 200-250 g)Dosage:100 mg/kg Administration:B.I.D., p.o. on day 7 after surgery, for 4 weeks Result:Increased ejection fraction, fraction shortening and preload recruitable stroke work.

FT011 | SHP-627

TGF-beta/Smad

TGFBR

TGFBR

Other Indications

Other Disease

1001288-58-9

351.3527

C20H17NO5

>98% (HPLC)

DMSO: ≥ 29 mg/mL

O=C(O)C1=CC=CC=C1NC(/C=C/C2=CC=C(OCC#C)C(OC)=C2)=O

Benzoic acid, 2-[[(2E)-3-[3-methoxy-4-(2-propyn-1-yloxy)phenyl]-1-oxo-2-propen-1-yl]amino]-

(-20℃)

With Ice Pack

≥ 2 years